BIOMARIN PHARMACEUTICAL INC Retained Earnings
BIOMARIN PHARMACEUTICAL INC (BMRN) had Retained Earnings of $304.50 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) $304.50M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) $259.73M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $154.21M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $200.78M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | $304.50M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $259.73M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $154.21M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $200.78M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $231.52M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$9.01M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | -$194.69M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$319.64M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$425.72M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | -$532.89M 10-Q · filed 2024-04-26 | |
| 2023-12-31 | -$621.55M 10-K · filed 2025-02-24 | |
| 2023-09-30 | -$641.93M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | -$682.31M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | -$738.35M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | -$789.20M 10-K · filed 2024-02-26 | |
| 2022-09-30 | -$788.95M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | -$777.23M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$804.89M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | -$930.76M 10-K · filed 2023-02-27 | -$925.69M 10-K · filed 2022-02-25 |
| 2021-09-30 | -$867.79M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | -$831.30M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | -$844.24M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | -$861.61M 10-K · filed 2022-02-25 | |
| 2020-09-30 | -$883.71M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | -$1.67B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$1.64B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | -$1.72B 10-K · filed 2021-02-26 | |
| 2019-09-30 | -$1.74B 10-Q/A · filed 2019-11-04 | |
| 2019-06-30 | -$1.79B 10-Q · filed 2019-08-02 | |
| 2019-03-31 | -$1.75B 10-Q · filed 2019-04-29 | |
| 2018-12-31 | -$1.69B 10-K · filed 2020-02-27 | |
| 2018-09-30 | -$1.69B 10-Q · filed 2018-10-26 | |
| 2018-06-30 | -$1.68B 10-Q · filed 2018-08-03 | |
| 2018-03-31 | -$1.66B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | -$1.64B 10-K · filed 2019-02-28 | |
| 2017-09-30 | -$1.59B 10-Q · filed 2017-10-31 | |
| 2017-06-30 | -$1.57B 10-Q · filed 2017-08-02 | |
| 2017-03-31 | -$1.54B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$1.52B 10-K · filed 2018-02-26 | |
| 2016-09-30 | -$1.57B 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$1.53B 10-Q · filed 2016-08-08 | |
| 2016-03-31 | -$1.11B 10-Q · filed 2016-05-02 | |
| 2015-12-31 | -$1.02B 10-K · filed 2017-02-27 | |
| 2015-09-30 | -$1.09B 10-Q · filed 2015-11-02 | |
| 2015-06-30 | -$999.26M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | -$917.27M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | -$849.77M 10-K · filed 2016-02-29 | |
| 2014-09-30 | -$779.97M 10-Q · filed 2014-10-28 | |
| 2014-06-30 | -$787.42M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | -$753.92M 10-Q · filed 2014-05-02 | |
| 2013-12-31 | -$715.80M 10-K · filed 2015-03-02 | |
| 2013-09-30 | -$653.81M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | -$600.79M 10-Q · filed 2013-07-29 | |
| 2013-03-31 | -$579.26M 10-Q · filed 2013-04-29 | |
| 2012-12-31 | -$539.45M 10-K · filed 2014-02-26 | |
| 2012-09-30 | -$486.44M 10-Q · filed 2012-10-29 | |
| 2012-06-30 | -$481.08M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | -$449.07M 10-Q · filed 2012-04-30 | |
| 2011-12-31 | -$425.10M 10-K · filed 2013-02-26 | |
| 2011-09-30 | -$398.37M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | -$380.71M 10-Q · filed 2011-08-01 | |
| 2011-03-31 | -$375.64M 10-Q · filed 2011-04-29 | |
| 2010-12-31 | -$371.26M 10-K · filed 2012-02-22 | |
| 2010-09-30 | -$359.08M 10-Q · filed 2010-10-29 | |
| 2010-06-30 | -$576.41M 10-Q · filed 2010-08-04 | |
| 2009-12-31 | -$577.08M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |